Similar articles for PMID: 32366442

Year	Number of Results
1992	1
1994	1
1995	1
1996	1
1999	1
2000	3
2004	1
2005	1
2006	1
2008	1
2010	2
2011	1
2012	2
2013	1
2014	4
2015	9
2016	8
2017	10
2018	25
2019	21
2020	3
2022	0

1

Targeted Therapy Followed by Cytotoxic Chemotherapy in Preoperative Patients With Locally Advanced Lung Adenocarcinoma.

Aoki M, Ueda K, Umehara T, Kamimura GO, Tokunaga T, Harada-Takeda A, Maeda K, Nagata T, Yokomakura N, Kariatsumari K, Nonaka Y, Imamura N, Morizono S, Sato M. Aoki M, et al. Anticancer Res. 2020 May;40(5):2911-2916. doi: 10.21873/anticanres.14268. Anticancer Res. 2020. PMID: 32366442

2

Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non-T790M mutations after progression on first-line EGFR-tyrosine kinase inhibitors.

Jiang Z, Zhang Y, Yang Y, Yue Z, Pan Z. Jiang Z, et al. Thorac Cancer. 2018 Sep;9(9):1151-1155. doi: 10.1111/1759-7714.12814. Epub 2018 Jul 20. Thorac Cancer. 2018. PMID: 30027579 Free PMC article.

3

Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001).

Ou W, Li N, Wang SY, Li J, Liu QW, Huang QA, Wang BX. Ou W, et al. Cancer. 2016 Mar 1;122(5):740-7. doi: 10.1002/cncr.29800. Epub 2015 Dec 23. Cancer. 2016. PMID: 26700505 Free article. Clinical Trial.

4

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial.

Markóczy Z, Sárosi V, Kudaba I, Gálffy G, Turay ÜY, Demirkazik A, Purkalne G, Somfay A, Pápai-Székely Z, Rásó E, Ostoros G. Markóczy Z, et al. BMC Cancer. 2018 May 25;18(1):598. doi: 10.1186/s12885-018-4283-z. BMC Cancer. 2018. PMID: 29801465 Free PMC article. Clinical Trial.

5

[Efficacy of first generation EGFR-TKIs and chemotherapy as first-line therapy in advanced lung adenocarcinoma patients with uncommon EGFR mutations].

Li HX, Wang ZZ, Zhang GW, Zhang MN, Zheng XX, Yang JP, Ma ZY, Wang HJ. Li HX, et al. Zhonghua Zhong Liu Za Zhi. 2019 Oct 23;41(10):783-791. doi: 10.3760/cma.j.issn.0253-3766.2019.10.012. Zhonghua Zhong Liu Za Zhi. 2019. PMID: 31648503 Chinese.

6

The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.

Yang CJ, Hung JY, Tsai MJ, Wu KL, Liu TC, Chou SH, Lee JY, Hsu JS, Huang MS, Chong IW. Yang CJ, et al. BMC Pharmacol Toxicol. 2017 May 10;18(1):21. doi: 10.1186/s40360-017-0130-0. BMC Pharmacol Toxicol. 2017. PMID: 28486985 Free PMC article.

7

Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.

Chen YF, Hsieh MS, Wu SG, Chang YL, Yu CJ, Yang JC, Yang PC, Shih JY. Chen YF, et al. J Thorac Oncol. 2016 Jul;11(7):1140-52. doi: 10.1016/j.jtho.2016.03.022. Epub 2016 Apr 16. J Thorac Oncol. 2016. PMID: 27094798 Free article.

8

Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability.

Germonpré P, Van den Wyngaert T. Germonpré P, et al. PLoS One. 2019 Apr 11;14(4):e0215135. doi: 10.1371/journal.pone.0215135. eCollection 2019. PLoS One. 2019. PMID: 30973926 Free PMC article. Clinical Trial.

9

[Association between the ALK Gene Status and the Efficacy of First-line  Pemetrexed Chemotherapy in Patients with Advanced Lung Adenocarcinoma].

Chen M, Cao H, Ji Y, Mao Y, Shen S, Li X. Chen M, et al. Zhongguo Fei Ai Za Zhi. 2017 Nov 20;20(11):732-736. doi: 10.3779/j.issn.1009-3419.2017.11.02. Zhongguo Fei Ai Za Zhi. 2017. PMID: 29167001 Free PMC article. Chinese.

10

Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours.

Yue-Yun C, Ye H, Yang F, Qing L, Pan-Pan L, Zhen-Yu D. Yue-Yun C, et al. Asian Pac J Cancer Prev. 2019 Aug 1;20(8):2415-2420. doi: 10.31557/APJCP.2019.20.8.2415. Asian Pac J Cancer Prev. 2019. PMID: 31450915 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed